Nurix Therapeutics (NRIX) Operating Leases (2021 - 2025)
Historic Operating Leases for Nurix Therapeutics (NRIX) over the last 5 years, with Q4 2025 value amounting to $55.7 million.
- Nurix Therapeutics' Operating Leases rose 17468.09% to $55.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $55.7 million, marking a year-over-year increase of 17468.09%. This contributed to the annual value of $55.7 million for FY2025, which is 17468.09% up from last year.
- Per Nurix Therapeutics' latest filing, its Operating Leases stood at $55.7 million for Q4 2025, which was up 17468.09% from $52.7 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Operating Leases ranged from a high of $55.7 million in Q4 2025 and a low of $2.6 million during Q3 2023
- For the 5-year period, Nurix Therapeutics' Operating Leases averaged around $19.8 million, with its median value being $20.0 million (2025).
- As far as peak fluctuations go, Nurix Therapeutics' Operating Leases plummeted by 6588.77% in 2023, and later surged by 67933.38% in 2024.
- Over the past 5 years, Nurix Therapeutics' Operating Leases (Quarter) stood at $9.2 million in 2021, then decreased by 29.98% to $6.4 million in 2022, then surged by 259.42% to $23.1 million in 2023, then dropped by 12.26% to $20.3 million in 2024, then skyrocketed by 174.68% to $55.7 million in 2025.
- Its Operating Leases stands at $55.7 million for Q4 2025, versus $52.7 million for Q3 2025 and $46.7 million for Q2 2025.